Last reviewed · How we verify
Eucrisa (Crisaborole)
Crisaborole inhibits phosphodiesterase 4, increasing intracellular cAMP levels for atopic dermatitis treatment.
EUCRISA is a topical PDE-4 inhibitor indicated for mild to moderate atopic dermatitis in patients 3 months and older. The drug demonstrates systemic absorption with 97% plasma protein binding and is substantially metabolized with renal excretion as the primary elimination route. Clinical drug interaction studies show no significant interactions with CYP450 substrates including warfarin. EUCRISA represents a targeted topical therapy option for atopic dermatitis management across pediatric and adult populations.
At a glance
| Generic name | Crisaborole |
|---|---|
| Sponsor | Anacor Pharms Inc |
| Drug class | PDE-4 inhibitor |
| Target | Phosphodiesterase 4 (PDE-4) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2016 |
Mechanism of action
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor that works by increasing intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.
Approved indications
- Atopic dermatitis
Common side effects
- Application site pain
- Dermatitis atopic
- Upper respiratory tract infection
- Nasopharyngitis
- Pyrexia
- Diarrhoea
- Application site pruritus
- Dermatitis contact
- Headache
- Dermatitis diaper
- Cough
- Procedural pain
Drug interactions
- Warfarin (CYP2C9 substrate)
Key clinical trials
- Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema (PHASE4)
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |